IgG4-Related Diseases Market: Epidemiology, Therapies, Companies, DelveInsight Forecast 2034

DelveInsight's new report on "IgG4-Related Diseases - Market Insights, Epidemiology, and Market Forecast-2034" provides an in-depth analysis of the disease, epidemiology, and market trends in the US, EU5 (Germany, Spain, Italy, France, UK), and Japan. Emerging therapies like Obexelimab (XmAb5871) are poised to drive market growth.

Discover about the IgG4-Related diseases market report @ https://www.delveinsight.com/report-store/igg4-related-disease-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Key Facts of the IgG4-Related Diseases Market Report:

• The IgG4-RD market was valued at ~USD 170 million in 2024, with strong CAGR growth projected through 2034.
• IgG4-RD is a systemic fibroinflammatory condition affecting organs like the pancreas, bile ducts, and kidneys, characterized by elevated IgG4 levels and plasma cell infiltration.
• In April 2025, Amgen's UPLIZNA received FDA approval as the first treatment for adults with IgG4-RD, earning Breakthrough Therapy Designation.
• Estimated 148,970 diagnosed prevalent cases in 7MM (US, EU4, UK, Japan) in 2024, with the US leading at ~56,800 cases (39,100 male, 17,700 female). Japan reported ~38,690 cases.
• Companies like Amgen, Zenas BioPharma, Bristol Myers Squibb, and Sanofi are advancing therapies; 20-30% of patients avoid systemic treatment, opting for surgery or monitoring.
• US market: ~USD 90 million in 2024; EU4+UK: ~USD 80 million; Japan: ~USD 6 million, with notable CAGR growth.
• Key players: Roche, AbbVie, Gilead Sciences, Takeda, and others developing new drugs. Leading Asian efforts include Mitsubishi Tanabe Pharma (Japan) partnering with Hansoh Pharma (China) on Inebilizumab (UPLIZNA®), a Phase 3 anti-CD19 monoclonal antibody that depletes CD19-positive B cells, targeting plasmablasts in IgG4-RD pathogenesis; their MITIGATE trial (NCT04540497) showed positive results with 87% flare risk reduction and significant remission, leading to FDA approval in April 2025 and Japan approval in November 2025. Kyowa Kirin (Japan) is exploring an anti-IL-4Rα monoclonal antibody in preclinical stages, aiming to modulate Th2 responses for fibro-inflammatory activity, with plans for early human trials by 2025. Taiwan and Korea show limited direct sponsorship, with no registered Phase 1–3 trials by local companies like OBI Pharma or Korean firms, though multinational trials include regional sites.

IgG4-Related Diseases Overview IgG4-RD is a chronic autoimmune disorder involving IgG4-positive plasma cell infiltration and elevated serum IgG4, affecting organs like salivary glands, pancreas, bile ducts, and less commonly the liver. It overlaps with conditions such as autoimmune pancreatitis and retroperitoneal fibrosis.

IgG4-Related Diseases Market Outlook The cause is unknown, with no cures available. Guidelines recommend glucocorticoids (e.g., prednisone) as first-line, sometimes with DMARDs. Plasmablasts serve as biomarkers. Pipeline therapies from Zenas BioPharma, Amgen, and Sanofi aim to transform treatment, contingent on pricing and reimbursement.

Discover how the IgG4-Related diseases market is rising in the coming years @ https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

IgG4-Related Disease Marketed Drugs

• UPLIZNA (inebilizumab): Amgen

IgG4-Related Diseases Emerging Drugs

• Obexelimab (XmAb5871): Zenas BioPharma and Bristol Myers Squibb

Scope of the IgG4-Related Diseases Market Report

• Study Period: 2020-2034
• Coverage: 7MM (US, EU5, Japan)
• Key Companies: Roche, AbbVie, Gilead Sciences, Takeda, and others
• Key Therapies: Obexelimab (XmAb5871), and others
• Therapeutic Assessment: Current marketed and emerging therapies
• Market Dynamics: Drivers, barriers, SWOT, PESTLE, Porter's five forces, BCG Matrix, market entry strategies
• Unmet Needs, KOL/Analyst Views, Market Access, Reimbursement

To know what's more in our IgG4-Related diseases report, visit https://www.delveinsight.com/report-store/igg4-related-disease-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Key Benefits of the IgG4-Related Diseases Market Report:

• Descriptive overview of epidemiology and market in 7MM.
• Insights into current/emerging therapies.
• Global historical/forecasted market with drug outreach.
• Strategic edge for business development via trend analysis.

Got queries? Click here to know more about the IgG4-Related diseases market Landscape https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Related report

IgG4-Related Disease - Epidemiology Forecast - 2034

DelveInsight’s “IgG4-Related Disease (IgG4-RD) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of IgG4-RD, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The leading IgG4-Related Disease Companies developing potential therapies include - Zenas BioPharma, Bristol Myers Squibb, Amgen, Sanofi, and others.

IgG4-Related Disease - Pipeline Insight, 2025

DelveInsight’s, “IgG4-Related Disease - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in IgG4-Related Disease pipeline landscape. The leading IgG4-Related Disease Companies developing potential therapies include - Zenas BioPharma, Bristol Myers Squibb, Amgen, Sanofi, and others.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com